<H3>Here is the press releaser for a new hand sanitizer. It doesn't look like it is on the market yet. Doug</H3>
<H3>ALDA Pharmaceuticals Develops Powerful New Hand Sanitizer </H3> TSX-V SYMBOL: APH
VANCOUVER, Jan. 31 /CNW/ - ALDA Pharmaceuticals Corp. (APH:TSX-V) (the
"Company") has completed the development of a powerful and safe hand sanitizer
based on its patent-pending T(3)6(R) technology. ALDA's infection control
technology has been proven to completely kill all 57 bacteria, viruses and
fungi on which it has been tested, including polio and TB, the two benchmark
micro-organisms that are known to be the most resistant to disinfectants. The
ability to kill polio and TB means that the new hand sanitizer is also
acknowledged to be effective against all bacteria and viruses including Avian
Flu, SARS, Norwalk Virus, HIV, Legionella and Hepatitis.
Dr. Terrance Owen, President and CEO of ALDA Pharmaceuticals Corp.,
comments, "People are becoming increasingly aware that many infectious
diseases are passed on through direct hand contact. ALDA is excited to enter
this marketplace with a technology that is effective against so many of these
easily transmittable diseases."
ALDA's therapeutic subsidiary, Sirona Therapeutics Corp., will
immediately pursue regulatory approval and commercialization in accordance
with its agreement with ALDA, after which the product will be available in
U.S., Canadian, Asian and European markets. The $9.4 billion infection
prevention products market in the U.S. is expected to grow 5% annually over
the next 4 years with the hand sanitizers becoming a growing portion of this
market.
About ALDA Pharmaceuticals
ALDA is pleased to add a powerful new hand sanitizer to its family of
wide spectrum, non-toxic, non-corrosive, biodegradable infection control
products based on its patent pending T(3)6(R) technology. The company trades
on the TSX Venture Exchange under the symbol APH.
</PRE>For further information:
Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com
Distribution & Sales Contact
Aaron Genereaux
(604) 521-8300
[email protected]
Investor Contact
Scott Young
(604) 288-7222
[email protected]
Insight Financial Marketing Network
Dean Meloni
(604) 694-8807
[email protected]
</PRE>